Ming‐Tsung Lin

654 total citations
34 papers, 483 citations indexed

About

Ming‐Tsung Lin is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Ming‐Tsung Lin has authored 34 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Epidemiology, 28 papers in Hepatology and 3 papers in Surgery. Recurrent topics in Ming‐Tsung Lin's work include Liver Disease Diagnosis and Treatment (26 papers), Hepatitis C virus research (20 papers) and Hepatitis B Virus Studies (17 papers). Ming‐Tsung Lin is often cited by papers focused on Liver Disease Diagnosis and Treatment (26 papers), Hepatitis C virus research (20 papers) and Hepatitis B Virus Studies (17 papers). Ming‐Tsung Lin collaborates with scholars based in Taiwan and United States. Ming‐Tsung Lin's co-authors include Tsung‐Hui Hu, Kuo‐Chin Chang, Ming‐Chao Tsai, Yi‐Hao Yen, Po‐Lin Tseng, Cheng‐Kun Wu, Chien‐Hung Chen, Sheng‐Nan Lu, Chao‐Hung Hung and Jing‐Houng Wang and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Ming‐Tsung Lin

33 papers receiving 477 citations

Peers

Ming‐Tsung Lin

EPIDE

HEPAT

SURGE

GASTR

Byung Soo Moon South Korea

Ferial El-Kalla Egypt

Abdelrahman Kobtan Egypt

Loai Mansour Egypt

Stylianos Karatapanis Greece

J. Toyota Japan

Pin‐I Hsu Taiwan

Oya Övünç Kurdaş Türkiye

Abed Zaitoun United Kingdom

Axel Hsu Hong Kong

Byung Soo Moon South Korea

Ming‐Tsung Lin

213 ×0.7

EPIDE

270 ×0.9

HEPAT

209 ×1.7

SURGE

33 ×0.6

GASTR

47 ×1.0

Citations per year, relative to Ming‐Tsung Lin Ming‐Tsung Lin (= 1×) peers Byung Soo Moon

Countries citing papers authored by Ming‐Tsung Lin

Since Specialization

Citations

This map shows the geographic impact of Ming‐Tsung Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Tsung Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Tsung Lin more than expected).

Fields of papers citing papers by Ming‐Tsung Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Tsung Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Tsung Lin. The network helps show where Ming‐Tsung Lin may publish in the future.

Co-authorship network of co-authors of Ming‐Tsung Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Tsung Lin. A scholar is included among the top collaborators of Ming‐Tsung Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Tsung Lin. Ming‐Tsung Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsai, Ming‐Chao, Chih‐Chi Wang, Wei‐Chen Lee, et al.. (2021). Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection. Liver Cancer. 11(1). 22–37. 15 indexed citations

Wang, Chih‐Chi, Chen‐Kai Chou, Yueh‐Wei Liu, et al.. (2021). Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLoS ONE. 16(3). e0247231–e0247231. 12 indexed citations

Hu, Tsung‐Hui, Sherry Yueh‐Hsia Chiu, Po‐Lin Tseng, et al.. (2020). Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan. Alimentary Pharmacology & Therapeutics. 52(11-12). 1695–1706. 14 indexed citations

Lin, Ming‐Tsung, Kuo‐Chin Chang, Yi‐Hao Yen, et al.. (2020). Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. Journal of the Formosan Medical Association. 120(1). 621–628. 1 indexed citations

Tsai, Ming‐Chao, Chao‐Cheng Huang, Yu‐Ching Wei, et al.. (2020). Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences. 21(6). 2060–2060. 6 indexed citations

Tsai, Ming‐Chao, Yi‐Hao Yen, Kuo‐Chin Chang, et al.. (2019). Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 19(1). 1169–1169. 15 indexed citations

Wu, Cheng‐Kun, Kuo‐Chin Chang, Sheng‐Nan Lu, et al.. (2018). Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. Journal of the Formosan Medical Association. 118(1). 504–513. 12 indexed citations

Yen, Yi‐Hao, Ming‐Tsung Lin, Fang‐Ying Kuo, et al.. (2017). The association between steatosis and diabetes with hepatocellular carcinoma in non‐genotype 3 chronic hepatitis C patients. Liver International. 38(6). 1064–1073. 14 indexed citations

Hu, Tsung‐Hui, Kuo‐Chin Chang, Po‐Lin Tseng, et al.. (2017). Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy. Medicine. 96(46). e8696–e8696. 9 indexed citations

10.

Yen, Yi‐Hao, Jung‐Fu Chen, Cheng‐Kun Wu, et al.. (2017). The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. Journal of the Formosan Medical Association. 116(11). 852–861. 10 indexed citations

11.

Yen, Yi‐Hao, Kuo‐Chin Chang, Ming‐Chao Tsai, et al.. (2017). Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. Journal of the Formosan Medical Association. 117(4). 268–275. 17 indexed citations

12.

Yen, Yi‐Hao, Jin‐Bor Chen, Ben‐Chung Cheng, et al.. (2017). Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study. PLoS ONE. 12(4). e0176027–e0176027. 14 indexed citations

13.

Wu, Cheng‐Kun, Kuo‐Chin Chang, Chao‐Hung Hung, et al.. (2016). Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. Journal of Antimicrobial Chemotherapy. 71(7). 1943–1947. 20 indexed citations

14.

Lin, Ming‐Tsung, Chih‐Chi Wang, Yu‐Fan Cheng, et al.. (2016). Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. PLoS ONE. 11(11). e0166157–e0166157. 12 indexed citations

15.

Tsai, Ming‐Chao, Chien‐Hung Chen, Po‐Lin Tseng, et al.. (2016). Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study. PLoS ONE. 11(3). e0149761–e0149761. 14 indexed citations

16.

Tsai, Ming‐Chao, Chia‐Hsiang Chen, Po‐Lin Tseng, et al.. (2015). Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clinical Microbiology and Infection. 22(1). 95.e1–95.e7. 50 indexed citations

17.

Tai, Wei‐Chen, Ming‐Tsung Lin, Tsung‐Hui Hu, et al.. (2014). Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomedical Journal. 37(5). 326–326. 23 indexed citations

18.

Chang, Kuo‐Chin, Po‐Lin Tseng, Yi‐Ying Wu, et al.. (2014). A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology. 13(5). 1017–1024. 46 indexed citations

19.

Lin, Ming‐Tsung, Yeh‐Pin Chou, Tsung‐Hui Hu, et al.. (2013). Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. Archives of Virology. 159(1). 29–37. 2 indexed citations

20.

Tseng, Po‐Lin, Te‐Chuan Chen, Chao‐Hung Hung, et al.. (2013). Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts. American Journal of Kidney Diseases. 62(4). 789–795. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact